MedTrace Logo

Phase II Study Comparing LR-GEM to R-GEM-P in Second-line Treatment of Diffuse Large B-cell Lymphoma (LEGEND)

NCT02060656 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 92

Last updated 2019-09-19

No results posted yet for this study

Summary

This is a randomised, phase II open-labelled two-arm study comparing R-GEM-P and LR-GEM in second-line treatment of Diffuse Large B-cell lymphoma. Eligible patients will be randomised 1:1 between R-GEM-P and LR-GEM.

Conditions

  • Diffuse Large B-Cell Lymphoma

Interventions

DRUG

Gemcitabine

1000mg/m2 IV D1, D8, D15 every 28 days

DRUG

Methylprednisolone

1000mg/m2 IV or PO D1-5 every 28 days

DRUG

Rituximab

375mg/m2 IV D1, D15 every 28 days

DRUG

Cisplatin

100mg/m2 IV D15 every 28 days

DRUG

Lenalidomide

25mg PO D1-21 every 28 days

Sponsors & Collaborators

  • Celgene Corporation

    collaborator INDUSTRY

  • Royal Marsden NHS Foundation Trust

    lead OTHER

Principal Investigators

  • David Cunningham, MD FRCP · Royal Marsden NHS Foundation Trust

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2018-02-28
Completion
2023-08-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02060656 on ClinicalTrials.gov